Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 52,527 shares of the specialty pharmaceutical company’s stock after selling 4,700 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $1,505,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its holdings in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after acquiring an additional 64,958 shares in the last quarter. Emerald Advisers LLC lifted its position in shares of Collegium Pharmaceutical by 27.2% during the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock worth $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Collegium Pharmaceutical by 17.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after buying an additional 116,327 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Collegium Pharmaceutical by 43.6% in the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after buying an additional 215,874 shares in the last quarter.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $29.05 on Friday. The stock’s 50-day moving average is $30.84 and its two-hundred day moving average is $33.51. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 1 year low of $27.84 and a 1 year high of $42.29. The firm has a market cap of $936.86 million, a price-to-earnings ratio of 12.52 and a beta of 0.82.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.